A practical guide to real‐world implementation of pre‐emptive therapy for Cytomegalovirus disease prevention in high‐risk seronegative liver transplant recipients with seropositive donors

Abstract

AbstractThe Comparison of Antiviral Preventative Strategies In Liver Transplant (CAPSIL) study showed pre‐emptive therapy (PET) to be superior to antiviral prophylaxis for Cytomegalovirus (CMV) disease prevention in high‐risk CMV seronegative liver transplant recipients (LTRs) with seropositive donors (D+R−). Despite the statistical superiority of PET over prophylaxis in research settings, PET is perceived as a logistically more complex strategy that requires careful coordination of weekly CMV PCR testing, prompt initiation of CMV antivirals upon viremia detection, and timely cessation of antivirals following viremia resolution. Transplant centers may be hesitant to use PET for CMV disease prevention in D+R− LTRs out of concern that PET coordination is not feasible in clinical practice. We recently described our experience using PET in CMV D+R− LTRs in a real‐world setting, and found it to be as effective for CMV disease prevention as PET performed as part of a clinical trial. Here, we describe a systematic approach for PET implementation in real‐world settings and provide practical tools to address anticipated challenges. This framework can support transplant programs in overcoming logistical barriers to PET and incorporating an evidence‐based and cost‐effective CMV prevention strategy into routine care for high‐risk CMV D+R− LTRs.